Teva Pharmaceutical (Germany) Investor Sentiment

TEV Stock  EUR 21.20  0.20  0.95%   
Roughly 52% of Teva Pharmaceutical's stockholders are presently thinking to get in. The analysis of current outlook of investing in Teva Pharmaceutical Industries suggests that some traders are interested regarding Teva Pharmaceutical's prospects. The current market sentiment, together with Teva Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Teva Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
Teva Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Teva daily returns and investor perception about the current price of Teva Pharmaceutical Industries as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at news.google.com         
Teva Pharmaceutical Industries Limited Receives 13.78 Consensus Price Target from Analysts - MarketB...
Google News at Macroaxis
over six months ago at news.google.com         
Teva Pharmaceutical Industries Target of Unusually High Options Trading - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Investors Buy High Volume of Call Options on Teva Pharmaceutical Industries - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Teva stock upgraded at J.P. Morgan on catalysts - Seeking Alpha
Google News at Macroaxis
over six months ago at news.google.com         
Teva Pharmaceutical Industries Limited Short Interest Update - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Those who invested in Teva Pharmaceutical Industries a year ago are up 32 percent - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Mondays P...
Google News at Macroaxis
over six months ago at news.google.com         
Piper Sandler upgrades Teva shares to overweight, target raised to 19 By Investing.com - Investing.c...
Google News at Macroaxis
over six months ago at news.google.com         
Should You Hold Teva Pharmaceutical Industries Ltd Stock Wednesday Morning - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
Teva Pharmaceutical Industries Limited CAO Sells 2945.42 in Stock - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up - Zacks Investment Research
Google News at Macroaxis
over six months ago at news.google.com         
Teva Stock, GSK Stock Put Up Bullish Fourth-Quarter Performances - Investors Business Daily
Google News at Macroaxis
over six months ago at news.google.com         
Teva stock raised to Buy at Jefferies - Seeking Alpha
Google News at Macroaxis
over six months ago at news.google.com         
Teva Pharmaceutical Industries Limiteds Business And Shares Still Trailing The Industry - Simply Wal...
Google News at Macroaxis
over six months ago at news.google.com         
Piper Sandler raises Teva to neutral, stock up 4 percent - Seeking Alpha
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Teva Pharmaceutical that are available to investors today. That information is available publicly through Teva media outlets and privately through word of mouth or via Teva internal channels. However, regardless of the origin, that massive amount of Teva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Teva Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Teva Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Teva Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Teva Pharmaceutical alpha.

Teva Pharmaceutical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Teva Stock analysis

When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bonds Directory
Find actively traded corporate debentures issued by US companies
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance